These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 20123960)

  • 1. Type I IFN controls chikungunya virus via its action on nonhematopoietic cells.
    Schilte C; Couderc T; Chretien F; Sourisseau M; Gangneux N; Guivel-Benhassine F; Kraxner A; Tschopp J; Higgs S; Michault A; Arenzana-Seisdedos F; Colonna M; Peduto L; Schwartz O; Lecuit M; Albert ML
    J Exp Med; 2010 Feb; 207(2):429-42. PubMed ID: 20123960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
    Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory monocytes mediate control of acute alphavirus infection in mice.
    Haist KC; Burrack KS; Davenport BJ; Morrison TE
    PLoS Pathog; 2017 Dec; 13(12):e1006748. PubMed ID: 29244871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease.
    Couderc T; Chrétien F; Schilte C; Disson O; Brigitte M; Guivel-Benhassine F; Touret Y; Barau G; Cayet N; Schuffenecker I; Desprès P; Arenzana-Seisdedos F; Michault A; Albert ML; Lecuit M
    PLoS Pathog; 2008 Feb; 4(2):e29. PubMed ID: 18282093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon Alpha, but Not Interferon Beta, Acts Early To Control Chronic Chikungunya Virus Pathogenesis.
    Locke MC; Fox LE; Dunlap BF; Young AR; Monte K; Lenschow DJ
    J Virol; 2022 Jan; 96(1):e0114321. PubMed ID: 34668781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation.
    Cook LE; Locke MC; Young AR; Monte K; Hedberg ML; Shimak RM; Sheehan KCF; Veis DJ; Diamond MS; Lenschow DJ
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
    Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
    EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation.
    Werneke SW; Schilte C; Rohatgi A; Monte KJ; Michault A; Arenzana-Seisdedos F; Vanlandingham DL; Higgs S; Fontanet A; Albert ML; Lenschow DJ
    PLoS Pathog; 2011 Oct; 7(10):e1002322. PubMed ID: 22028657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.
    Pal P; Dowd KA; Brien JD; Edeling MA; Gorlatov S; Johnson S; Lee I; Akahata W; Nabel GJ; Richter MK; Smit JM; Fremont DH; Pierson TC; Heise MT; Diamond MS
    PLoS Pathog; 2013; 9(4):e1003312. PubMed ID: 23637602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmacytoid Dendritic Cells Mediate Control of Ross River Virus Infection via a Type I Interferon-Dependent, MAVS-Independent Mechanism.
    Haist KC; Carpentier KS; Davenport BJ; Morrison TE
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33361425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutting edge: independent roles for IRF-3 and IRF-7 in hematopoietic and nonhematopoietic cells during host response to Chikungunya infection.
    Schilte C; Buckwalter MR; Laird ME; Diamond MS; Schwartz O; Albert ML
    J Immunol; 2012 Apr; 188(7):2967-71. PubMed ID: 22371392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Methyltransferase-Like Domain of Chikungunya Virus nsP2 Inhibits the Interferon Response by Promoting the Nuclear Export of STAT1.
    Göertz GP; McNally KL; Robertson SJ; Best SM; Pijlman GP; Fros JJ
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.
    Fox JM; Diamond MS
    J Immunol; 2016 Dec; 197(11):4210-4218. PubMed ID: 27864552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An essential role of antibodies in the control of Chikungunya virus infection.
    Lum FM; Teo TH; Lee WW; Kam YW; Rénia L; Ng LF
    J Immunol; 2013 Jun; 190(12):6295-302. PubMed ID: 23670192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infection of myofibers contributes to increased pathogenicity during infection with an epidemic strain of chikungunya virus.
    Rohatgi A; Corbo JC; Monte K; Higgs S; Vanlandingham DL; Kardon G; Lenschow DJ
    J Virol; 2014 Mar; 88(5):2414-25. PubMed ID: 24335291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity.
    Lum FM; Couderc T; Chia BS; Ong RY; Her Z; Chow A; Leo YS; Kam YW; Rénia L; Lecuit M; Ng LFP
    Sci Rep; 2018 Jan; 8(1):1860. PubMed ID: 29382880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the differential response of two human fibroblast cell lines following Chikungunya virus infection.
    Thon-Hon VG; Denizot M; Li-Pat-Yuen G; Giry C; Jaffar-Bandjee MC; Gasque P
    Virol J; 2012 Sep; 9():213. PubMed ID: 22992396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection.
    Kam YW; Simarmata D; Chow A; Her Z; Teng TS; Ong EK; Rénia L; Leo YS; Ng LF
    J Infect Dis; 2012 Apr; 205(7):1147-54. PubMed ID: 22389226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Conditions Enable IFNAR-Independent Type I Interferon Production by Peritoneal CD11b+ Cells upon Thogoto Virus Infection.
    Kochs G; Anzaghe M; Kronhart S; Wagner V; Gogesch P; Scheu S; Lienenklaus S; Waibler Z
    J Virol; 2016 Oct; 90(20):9330-7. PubMed ID: 27512061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.